| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10917740 | Radiotherapy and Oncology | 2016 | 6 Pages |
Abstract
RT utilization has decreased following incorporation of Rituximab for first line treatment of DLBCL. RT use is associated with improved OS in both pre- and post-Rituximab eras, suggesting that RT should continue to be used for management of early stage DLBCL, even in the era of Rituximab.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Waqar Haque, Bouthaina Dabaja, Anne Tann, Mohammad Khan, Sean Szeja, E. Brian Butler, Bin S. Teh,